.Nature Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a median consequence of 11 months, clients with metastatic intestinal lumps who obtained biomarker-matched treatments based upon distributing tumor DNA profiling revealed a higher scientific advantage than those receiving unrivaled treatment.